Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marta Mosca

Showing results (331-340 of 377) with videos related to

Pageof 38
Sort By:
The Lancet. Rheumatology|January 24, 2026
Patient partnership model in rare and complex rheumatological conditions: research and beyond in European Reference Network ReCONNETJeanette Andersen, Rosaria Talaric, Diana Marinello, et al.
Journal of Translational Autoimmunity|January 1, 2024
Long-term outcomes of COVID-19 vaccination in patients with rare and complex connective tissue diseases: The ERN-ReCONNET VACCINATE studyChiara Tani, Chiara Cardelli, Roberto Depascale, et al.
RMD Open|December 20, 2018
Systemic lupus erythematosus: state of the art on clinical practice guidelinesFarah Tamirou, Laurent Arnaud, Rosaria Talarico, et al.
RMD Open|November 8, 2018
Systemic sclerosis: state of the art on clinical practice guidelinesVanessa Smith, Carlo Alberto Scirè, Rosaria Talarico, et al.
Scientific Reports|October 13, 2025
Factors influencing the choice of non-biologic versus biologic immunosuppressive therapy in systemic lupus erythematosusAlessandra Bortoluzzi, Antonio Marangoni, Ettore Silvagni, et al.
Journal of Autoimmunity|October 2, 2021
Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohortMariele Gatto, Francesca Saccon, Laura Andreoli, et al.
Frontiers in Pharmacology|April 20, 2019
Long-Term Retention Rate of Anakinra in Adult Onset Still's Disease and Predictive Factors for Treatment ResponseAntonio Vitale, Giulio Cavalli, Serena Colafrancesco, et al.
Frontiers in Pharmacology|November 9, 2016
A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational StudyAntonio Vitale, Antonella Insalaco, Paolo Sfriso, et al.
Frontiers in Pharmacology|June 30, 2017
Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Still's Disease: A Multicentre Retrospective Observational StudySerena Colafrancesco, Roberta Priori, Guido Valesini, et al.
The Lancet. Rheumatology|May 26, 2025
ERN ReCONNET-SLICC-SLEuro expert consensus on the therapeutic management of rare systemic lupus erythematosus manifestationsLaurent Arnaud, Guillermo Ruiz-Irastorza, Cynthia Aranow, et al.
Pageof 38

Showing results (331-340 of 377) with videos related to

Sort By:
Pageof 38
The Lancet. Rheumatology|January 24, 2026
Patient partnership model in rare and complex rheumatological conditions: research and beyond in European Reference Network ReCONNETJeanette Andersen, Rosaria Talaric, Diana Marinello, et al.
Journal of Translational Autoimmunity|January 1, 2024
Long-term outcomes of COVID-19 vaccination in patients with rare and complex connective tissue diseases: The ERN-ReCONNET VACCINATE studyChiara Tani, Chiara Cardelli, Roberto Depascale, et al.
RMD Open|December 20, 2018
Systemic lupus erythematosus: state of the art on clinical practice guidelinesFarah Tamirou, Laurent Arnaud, Rosaria Talarico, et al.
RMD Open|November 8, 2018
Systemic sclerosis: state of the art on clinical practice guidelinesVanessa Smith, Carlo Alberto Scirè, Rosaria Talarico, et al.
Scientific Reports|October 13, 2025
Factors influencing the choice of non-biologic versus biologic immunosuppressive therapy in systemic lupus erythematosusAlessandra Bortoluzzi, Antonio Marangoni, Ettore Silvagni, et al.
Journal of Autoimmunity|October 2, 2021
Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohortMariele Gatto, Francesca Saccon, Laura Andreoli, et al.
Frontiers in Pharmacology|April 20, 2019
Long-Term Retention Rate of Anakinra in Adult Onset Still's Disease and Predictive Factors for Treatment ResponseAntonio Vitale, Giulio Cavalli, Serena Colafrancesco, et al.
Frontiers in Pharmacology|November 9, 2016
A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational StudyAntonio Vitale, Antonella Insalaco, Paolo Sfriso, et al.
Frontiers in Pharmacology|June 30, 2017
Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Still's Disease: A Multicentre Retrospective Observational StudySerena Colafrancesco, Roberta Priori, Guido Valesini, et al.
The Lancet. Rheumatology|May 26, 2025
ERN ReCONNET-SLICC-SLEuro expert consensus on the therapeutic management of rare systemic lupus erythematosus manifestationsLaurent Arnaud, Guillermo Ruiz-Irastorza, Cynthia Aranow, et al.
Pageof 38